151
|
Munder A, Moskovitz Y, Meir A, Kahremany S, Levy L, Kolitz-Domb M, Cohen G, Shtriker E, Viskind O, Lellouche JP, Senderowitz H, Chessler SD, Korshin EE, Ruthstein S, Gruzman A. Neuroligin-2-derived peptide-covered polyamidoamine-based (PAMAM) dendrimers enhance pancreatic β-cells' proliferation and functions. MEDCHEMCOMM 2019; 10:280-293. [PMID: 30881615 PMCID: PMC6390468 DOI: 10.1039/c8md00419f] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Accepted: 12/11/2018] [Indexed: 01/02/2023]
Abstract
Pancreatic β-cell membranes and presynaptic areas of neurons contain analogous protein complexes that control the secretion of bioactive molecules. These complexes include the neuroligins (NLs) and their binding partners, the neurexins (NXs). It has been recently reported that both insulin secretion and the proliferation rates of β-cells increase when cells are co-cultured with full-length NL-2 clusters. The pharmacological use of full-length protein is always problematic due to its unfavorable pharmacokinetic properties. Thus, NL-2-derived short peptide was conjugated to the surface of polyamidoamine-based (PAMAM) dendrimers. This nanoscale composite improved β-cell functions in terms of the rate of proliferation, glucose-stimulated insulin secretion (GSIS), and functional maturation. This functionalized dendrimer also protected β-cells under cellular stress conditions. In addition, various novel peptidomimetic scaffolds of NL-2-derived peptide were designed, synthesized, and conjugated to the surface of PAMAM in order to increase the biostability of the conjugates. However, after being covered by peptidomimetics, PAMAM dendrimers were inactive. Thus, the original peptide-based PAMAM dendrimer is a leading compound for continued research that might provide a unique starting point for designing an innovative class of antidiabetic therapeutics that possess a unique mode of action.
Collapse
Affiliation(s)
- Anna Munder
- Department of Chemistry , Faculty of Exact Sciences , Bar-Ilan University , Ramat-Gan , Israel . ;
| | - Yoni Moskovitz
- Department of Chemistry , Faculty of Exact Sciences , Bar-Ilan University , Ramat-Gan , Israel . ;
| | - Aviv Meir
- Department of Chemistry , Faculty of Exact Sciences , Bar-Ilan University , Ramat-Gan , Israel . ;
| | - Shirin Kahremany
- Department of Chemistry , Faculty of Exact Sciences , Bar-Ilan University , Ramat-Gan , Israel . ;
- Department of Pharmacology , Cleveland Center for Membrane and Structural Biology , School of Medicine , Case Western Reserve University , Cleveland , OH , USA
| | - Laura Levy
- Department of Chemistry , Faculty of Exact Sciences , Bar-Ilan University , Ramat-Gan , Israel . ;
| | - Michal Kolitz-Domb
- Department of Chemistry , Faculty of Exact Sciences , Bar-Ilan University , Ramat-Gan , Israel . ;
| | - Guy Cohen
- Skin Research Institute , Dead Sea and Arava Research Center , Masada , Israel
| | - Efrat Shtriker
- Department of Chemistry , Faculty of Exact Sciences , Bar-Ilan University , Ramat-Gan , Israel . ;
| | - Olga Viskind
- Department of Chemistry , Faculty of Exact Sciences , Bar-Ilan University , Ramat-Gan , Israel . ;
| | - Jean-Paul Lellouche
- Department of Chemistry , Faculty of Exact Sciences , Bar-Ilan University , Ramat-Gan , Israel . ;
- Nanomaterials Research Center , Institute of Nanotechnology & Advanced Materials (BINA) , Bar-Ilan University , Ramat-Gan , Israel
| | - Hanoch Senderowitz
- Department of Chemistry , Faculty of Exact Sciences , Bar-Ilan University , Ramat-Gan , Israel . ;
| | - Steven D Chessler
- Division of Endocrinology, Diabetes & Metabolism , Department of Medicine , University of California , Irvine , CA , USA
| | - Edward E Korshin
- Department of Chemistry , Faculty of Exact Sciences , Bar-Ilan University , Ramat-Gan , Israel . ;
| | - Sharon Ruthstein
- Department of Chemistry , Faculty of Exact Sciences , Bar-Ilan University , Ramat-Gan , Israel . ;
| | - Arie Gruzman
- Department of Chemistry , Faculty of Exact Sciences , Bar-Ilan University , Ramat-Gan , Israel . ;
| |
Collapse
|
152
|
Dahmani FZ, Zhong D, Qi Y, Dahmani AEG, Xie T, Zhou B, Li W, Yao K, Li L, Zhou M. A size-tunable and multi-responsive nanoplatform for deep tumor penetration and targeted combinatorial radio-/chemotherapy. J Mater Chem B 2019. [DOI: 10.1039/c9tb00716d] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We report a versatile nanoplatform with size tunability, pH-responsiveness, active targeting and radio-/chemotherapeutic features as an efficient tool for tumor therapy.
Collapse
Affiliation(s)
- Fatima Zohra Dahmani
- Eye Center, the Second Affiliated Hospital
- Zhejiang University School of Medicine
- Hangzhou 310009
- China
- Institute of Translational Medicine
| | - Danni Zhong
- Institute of Translational Medicine
- Zhejiang University
- Hangzhou 310009
- China
| | - Yuchen Qi
- Institute of Translational Medicine
- Zhejiang University
- Hangzhou 310009
- China
| | | | - Tingting Xie
- Institute of Translational Medicine
- Zhejiang University
- Hangzhou 310009
- China
| | - Bo Zhou
- Institute of Translational Medicine
- Zhejiang University
- Hangzhou 310009
- China
| | - Wanli Li
- Institute of Translational Medicine
- Zhejiang University
- Hangzhou 310009
- China
| | - Ke Yao
- Eye Center, the Second Affiliated Hospital
- Zhejiang University School of Medicine
- Hangzhou 310009
- China
- Zhejiang Provincial Key Lab of Ophthalmology
| | - Lei Li
- Shanghai Key Laboratory of Regulatory Biology
- Institute of Biomedical Sciences
- School of Life Sciences
- East China Normal University
- Shanghai 200241
| | - Min Zhou
- Eye Center, the Second Affiliated Hospital
- Zhejiang University School of Medicine
- Hangzhou 310009
- China
- Institute of Translational Medicine
| |
Collapse
|
153
|
Cong H, Zhou L, Meng Q, Zhang Y, Yu B, Shen Y, Hu H. Preparation and evaluation of PAMAM dendrimer-based polymer gels physically cross-linked by hydrogen bonding. Biomater Sci 2019; 7:3918-3925. [DOI: 10.1039/c9bm00960d] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Dendrimer-based polymer gels with good antibacterial properties and anti-inflammatory properties were prepared without any covalent bonding cross-linking agents.
Collapse
Affiliation(s)
- Hailin Cong
- Institute of Biomedical Materials and Engineering
- College of Materials Science and Engineering
- Qingdao University
- Qingdao
- China
| | - Liping Zhou
- Institute of Biomedical Materials and Engineering
- College of Materials Science and Engineering
- Qingdao University
- Qingdao
- China
| | - Qingye Meng
- Institute of Biomedical Materials and Engineering
- College of Materials Science and Engineering
- Qingdao University
- Qingdao
- China
| | - Yixin Zhang
- Institute of Biomedical Materials and Engineering
- College of Materials Science and Engineering
- Qingdao University
- Qingdao
- China
| | - Bing Yu
- Institute of Biomedical Materials and Engineering
- College of Materials Science and Engineering
- Qingdao University
- Qingdao
- China
| | - Youqing Shen
- Institute of Biomedical Materials and Engineering
- College of Materials Science and Engineering
- Qingdao University
- Qingdao
- China
| | - Hao Hu
- Institute of Biomedical Materials and Engineering
- College of Materials Science and Engineering
- Qingdao University
- Qingdao
- China
| |
Collapse
|
154
|
Rompicharla SVK, Kumari P, Bhatt H, Ghosh B, Biswas S. Biotin functionalized PEGylated poly(amidoamine) dendrimer conjugate for active targeting of paclitaxel in cancer. Int J Pharm 2018; 557:329-341. [PMID: 30599231 DOI: 10.1016/j.ijpharm.2018.12.069] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Revised: 12/05/2018] [Accepted: 12/17/2018] [Indexed: 11/20/2022]
Abstract
In the current study, we employed poly(amidoamine) (PAMAM) dendrimers of generation 4 (G4) to deliver paclitaxel (PTX), a poorly soluble anti-cancer agent precisely to cancer cells via its conjugation on dendrimer surface. Further, G4 PAMAM has been PEGylated (PEG) and tagged with Biotin, an essential micronutrient for cellular functions, receptors of which are overexpressed in certain cancers. The synthesized multifunctional conjugates were characterized by 1H NMR and zeta potential analysis techniques. In addition, the conjugates were evaluated in vitro in cell monolayers and 3D spheroids of biotin receptor over-expressed A549 cell line (human non-small cell lung cancer). G4 PTX PEG-Biotin conjugate penetrated at significantly higher extent in monolayers as well as spheroids as studied by flow cytometry and confocal microscopy by visualizing the cells at varied depth. The G4 PTX PEG-Biotin conjugate demonstrated higher cytotoxicity compared to free PTX and G4 PTX PEG conjugate as assessed by MTT assay in monolayers and Presto Blue assay in detached spheroidal cells. G4 PTX PEG-Biotin demonstrated significant inhibition of growth of tumor spheroids. Therefore, the newly synthesized biotin anchored PTX-conjugated dendrimer system is promising and could be further explored for efficiently delivering PTX to biotin receptor overexpressed cancers.
Collapse
Affiliation(s)
- Sri Vishnu Kiran Rompicharla
- Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Medchal, Hyderabad, Telangana 500078, India
| | - Preeti Kumari
- Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Medchal, Hyderabad, Telangana 500078, India
| | - Himanshu Bhatt
- Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Medchal, Hyderabad, Telangana 500078, India
| | - Balaram Ghosh
- Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Medchal, Hyderabad, Telangana 500078, India
| | - Swati Biswas
- Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Medchal, Hyderabad, Telangana 500078, India.
| |
Collapse
|
155
|
De Carlo E, Schiappacassi M, Urbani M, Doliana R, Baldassarre G, Da Ros V, Santarossa S, Chimienti E, Berto E, Fratino L, Bearz A. Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report. Onco Targets Ther 2018; 11:8945-8950. [PMID: 30573982 PMCID: PMC6292407 DOI: 10.2147/ott.s184745] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Background The use of tyrosine kinase inhibitors (TKIs) of ALK is the therapy of choice for ALK-fusion patients. Unfortunately, all patients under this kind of treatment eventually develop acquired resistance through several well-known mechanisms, such as acquisition of a secondary mutation within the kinase domain, activation of a bypass signaling pathway, or a histological change like small-cell lung cancer transformation. At the time of progression, a tissue re-biopsy may give important molecular and morphological information regarding the mechanisms driving resistance to ALK TKIs. However, this procedure is not always feasible and it may not reflect the tumor heterogeneity, and therefore gives incomplete information. To overcome these drawbacks, the analysis of circulating tumor DNA (ctDNA) isolated from plasma, the so-called liquid biopsy, is emerging as a noninvasive and useful tool for detecting resistance mutations. Secondary resistance mutations are common in second-generation TKIs resistant patients and among these, Gly1202Arg (p.G1202R) emerged as the most frequent mutation. Case presentation We have treated an ALK-positive lung adenocarcinoma patient with a sequential strategy of ALK TKIs. Patient follow-up was performed combining clinical, radiological, and molecular profiling. ctDNA was isolated from plasma and by means of ultra-deep next generation sequencing; we searched for secondary ALK resistance mutations on exons 21-25. ALK mutation Gly1202Arg (G1202R) was detected. We have documented consistency between plasma levels of G1202R mutation and radiological progression or improvement. Conclusion Liquid biopsy appears to be a promising tool to anticipate progression and to drive the therapeutic strategy based upon ALK resistance mutations.
Collapse
Affiliation(s)
- Elisa De Carlo
- Clinical Oncology Department, IRCCS CRO Centro di Riferimento Oncologico Aviano, Aviano, Italy,
| | - Monica Schiappacassi
- Molecular Oncology Department, IRCCS CRO Centro di Riferimento Oncologico Aviano, Aviano, Italy
| | - Martina Urbani
- Radiology Department, IRCCS CRO Centro di Riferimento Oncologico Aviano, Aviano, Italy
| | - Roberto Doliana
- Molecular Oncology Department, IRCCS CRO Centro di Riferimento Oncologico Aviano, Aviano, Italy
| | - Gustavo Baldassarre
- Molecular Oncology Department, IRCCS CRO Centro di Riferimento Oncologico Aviano, Aviano, Italy
| | - Valentina Da Ros
- Clinical Oncology Department, IRCCS CRO Centro di Riferimento Oncologico Aviano, Aviano, Italy,
| | - Sandra Santarossa
- Clinical Oncology Department, IRCCS CRO Centro di Riferimento Oncologico Aviano, Aviano, Italy,
| | - Emanuela Chimienti
- Clinical Oncology Department, IRCCS CRO Centro di Riferimento Oncologico Aviano, Aviano, Italy,
| | - Eleonora Berto
- Clinical Oncology Department, IRCCS CRO Centro di Riferimento Oncologico Aviano, Aviano, Italy,
| | - Lucia Fratino
- Clinical Oncology Department, IRCCS CRO Centro di Riferimento Oncologico Aviano, Aviano, Italy,
| | - Alessandra Bearz
- Clinical Oncology Department, IRCCS CRO Centro di Riferimento Oncologico Aviano, Aviano, Italy,
| |
Collapse
|
156
|
Liu H, Dong H, Zhou N, Dong S, Chen L, Zhu Y, Hu HM, Mou Y. SPIO Enhance the Cross-Presentation and Migration of DCs and Anionic SPIO Influence the Nanoadjuvant Effects Related to Interleukin-1β. NANOSCALE RESEARCH LETTERS 2018; 13:409. [PMID: 30570682 PMCID: PMC6301900 DOI: 10.1186/s11671-018-2802-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Accepted: 11/14/2018] [Indexed: 05/11/2023]
Abstract
Superparamagnetic iron oxide nanoparticles (SPIO) have been synthesized and explored for use as carriers of various nanoadjuvants via loading into dendritic cells (DCs). In our study, homogeneous and superparamagnetic nanoparticles are susceptible to internalization by DCs and SPIO-pulsed DCs showed excellent biocompatibility and capacity for ovalbumin (OVA) cross-presentation. Herein, we found that SPIO-loaded DCs can promote the maturation and migration of DCs in vitro. SPIO coated with 3-aminopropyltrimethoxysilane (APTS) and meso-2,3-dimercaptosuccinic acid (DMSA), which present positive and negative charges, respectively, were prepared. We aimed to investigate whether the surface charge of SPIO can affect the antigen cross-presentation of the DCs. Additionally, the formation of interleukin-1β (IL-1β) was examined after treatment with oppositely charged SPIO to identify the nanoadjuvants mechanism. In conclusion, our results suggest that SPIO are biocompatible and can induce the migration of DCs into secondary lymph nodes. SPIO coated with APTS (SPIO/A+) exhibited excellent adjuvant potentials for the promotion of antigen cross-presentation and T cell activation and surpassed that of DMSA-coated nanoparticles (SPIO/D-). This process may be related to the secretion of IL-1β. Our study provides insights into the predictive modification of nanoadjuvants, which will be valuable in DC vaccine design and could lead to the creation of new adjuvants for applications in vaccines for humans.
Collapse
Affiliation(s)
- Hui Liu
- Central Laboratory, Nanjing Stomatological Hospital, Medical School of Nanjing University, #30 Zhongyang Road, Nanjing, 210008 Jiangsu China
| | - Heng Dong
- Central Laboratory, Nanjing Stomatological Hospital, Medical School of Nanjing University, #30 Zhongyang Road, Nanjing, 210008 Jiangsu China
- Laboratory of Cancer Immunobiology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR USA
| | - Na Zhou
- Central Laboratory, Nanjing Stomatological Hospital, Medical School of Nanjing University, #30 Zhongyang Road, Nanjing, 210008 Jiangsu China
| | - Shiling Dong
- Central Laboratory, Nanjing Stomatological Hospital, Medical School of Nanjing University, #30 Zhongyang Road, Nanjing, 210008 Jiangsu China
| | - Lin Chen
- Central Laboratory, Nanjing Stomatological Hospital, Medical School of Nanjing University, #30 Zhongyang Road, Nanjing, 210008 Jiangsu China
| | - Yanxiang Zhu
- Central Laboratory, Nanjing Stomatological Hospital, Medical School of Nanjing University, #30 Zhongyang Road, Nanjing, 210008 Jiangsu China
| | - Hong-ming Hu
- Laboratory of Cancer Immunobiology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR USA
| | - Yongbin Mou
- Central Laboratory, Nanjing Stomatological Hospital, Medical School of Nanjing University, #30 Zhongyang Road, Nanjing, 210008 Jiangsu China
| |
Collapse
|
157
|
Yamagami M, Tajima T, Ishimoto K, Miyake H, Michiue H, Takaguchi Y. Physical modification of carbon nanotubes with a dendrimer bearing terminal mercaptoundecahydrododecaborates (Na
2
B
12
H
11
S). HETEROATOM CHEMISTRY 2018. [DOI: 10.1002/hc.21467] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- Masahiro Yamagami
- Graduate School of Environmental and Life ScienceOkayama University Okayama Japan
| | - Tomoyuki Tajima
- Graduate School of Environmental and Life ScienceOkayama University Okayama Japan
| | - Kango Ishimoto
- Graduate School of Environmental and Life ScienceOkayama University Okayama Japan
| | - Hideaki Miyake
- Graduate School of Sciences and Technology for InnovationYamaguchi University Yamaguchi Japan
| | | | - Yutaka Takaguchi
- Graduate School of Environmental and Life ScienceOkayama University Okayama Japan
| |
Collapse
|
158
|
Ray S, Li Z, Hsu CH, Hwang LP, Lin YC, Chou PT, Lin YY. Dendrimer- and copolymer-based nanoparticles for magnetic resonance cancer theranostics. Theranostics 2018; 8:6322-6349. [PMID: 30613300 PMCID: PMC6299700 DOI: 10.7150/thno.27828] [Citation(s) in RCA: 58] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Accepted: 09/20/2018] [Indexed: 01/06/2023] Open
Abstract
Cancer theranostics is one of the most important approaches for detecting and treating patients at an early stage. To develop such a technique, accurate detection, specific targeting, and controlled delivery are the key components. Various kinds of nanoparticles have been proposed and demonstrated as potential nanovehicles for cancer theranostics. Among them, polymer-like dendrimers and copolymer-based core-shell nanoparticles could potentially be the best possible choices. At present, magnetic resonance imaging (MRI) is widely used for clinical purposes and is generally considered the most convenient and noninvasive imaging modality. Superparamagnetic iron oxide (SPIO) and gadolinium (Gd)-based dendrimers are the major nanostructures that are currently being investigated as nanovehicles for cancer theranostics using MRI. These structures are capable of specific targeting of tumors as well as controlled drug or gene delivery to tumor sites using pH, temperature, or alternating magnetic field (AMF)-controlled mechanisms. Recently, Gd-based pseudo-porous polymer-dendrimer supramolecular nanoparticles have shown 4-fold higher T1 relaxivity along with highly efficient AMF-guided drug release properties. Core-shell copolymer-based nanovehicles are an equally attractive alternative for designing contrast agents and for delivering anti-cancer drugs. Various copolymer materials could be used as core and shell components to provide biostability, modifiable surface properties, and even adjustable imaging contrast enhancement. Recent advances and challenges in MRI cancer theranostics using dendrimer- and copolymer-based nanovehicles have been summarized in this review article, along with new unpublished research results from our laboratories.
Collapse
Affiliation(s)
- Sayoni Ray
- Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, USA
| | - Zhao Li
- Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, USA
| | - Chao-Hsiung Hsu
- Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, USA
- Department of Chemistry, National Taiwan University, Taipei 10617, Taiwan
| | - Lian-Pin Hwang
- Department of Chemistry, National Taiwan University, Taipei 10617, Taiwan
| | - Ying-Chih Lin
- Department of Chemistry, National Taiwan University, Taipei 10617, Taiwan
| | - Pi-Tai Chou
- Department of Chemistry, National Taiwan University, Taipei 10617, Taiwan
| | - Yung-Ya Lin
- Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, USA
| |
Collapse
|
159
|
Attia N, Mashal M, Soto-Sánchez C, Martínez-Navarrete G, Fernández E, Grijalvo S, Eritja R, Puras G, Pedraz JL. Gene transfer to rat cerebral cortex mediated by polysorbate 80 and poloxamer 188 nonionic surfactant vesicles. DRUG DESIGN DEVELOPMENT AND THERAPY 2018; 12:3937-3949. [PMID: 30510402 PMCID: PMC6248232 DOI: 10.2147/dddt.s178532] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Background Gene therapy can be an intriguing therapeutic option in wide-ranging neurological disorders. Though nonviral gene carriers represent a safer delivery system to their viral counterparts, a thorough design of such vehicles is crucial to enhance their transfection properties. Purpose This study evaluated the effects of combined use of two nonionic surfactants, poloxamer 188 (P) and polysorbate 80 (P80) into nanovesicles – based on 2,3-di(tetradecyloxy)propan-1-amine cationic lipid (D) – destined for gene delivery to central nervous system cells. Methods Niosome formulations without and with poloxamer 188 (DP80 and DPP80, respectively) were prepared by the reverse-phase evaporation technique and characterized in terms of size, surface charge, and morphology. After the addition of pCMS-EGFP plasmid, the binding efficiency to the niosomes was evaluated in agarose gel electrophoresis assays. Additionally, transfection efficiency of complexes was also evaluated in in vitro and in vivo conditions. Results In vitro experiments on NT2 cells revealed that the complexes based on a surfactant combination (DPP80) enhanced cellular uptake and viability when compared with the DP80 counterparts. Interestingly, DPP80 complexes showed protein expression in glial cells after administration into the cerebral cortices of rats. Conclusion These data provide new insights for glia-centered approach for gene therapy of nervous system disorders using cationic nanovesicles, where nonionic surfactants play a pivotal role.
Collapse
Affiliation(s)
- Noha Attia
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain, ; .,Medical Histology and Cell Biology Department, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.,Department of Basic Sciences, The American University of Antigua-College of Medicine, Coolidge, Antigua and Barbuda
| | - Mohamed Mashal
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain, ;
| | - Cristina Soto-Sánchez
- Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain, ; .,Neuroprothesis and Neuroengineering Research Group, Miguel Hernández University, Elche, Spain
| | - Gema Martínez-Navarrete
- Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain, ; .,Neuroprothesis and Neuroengineering Research Group, Miguel Hernández University, Elche, Spain
| | - Eduardo Fernández
- Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain, ; .,Neuroprothesis and Neuroengineering Research Group, Miguel Hernández University, Elche, Spain
| | - Santiago Grijalvo
- Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain, ; .,Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain
| | - Ramón Eritja
- Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain, ; .,Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Spain
| | - Gustavo Puras
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain, ; .,Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain, ;
| | - Jose Luis Pedraz
- NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain, ; .,Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain, ;
| |
Collapse
|
160
|
Cheng WJ, Chen LC, Ho HO, Lin HL, Sheu MT. Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy. Int J Nanomedicine 2018; 13:7079-7094. [PMID: 30464460 PMCID: PMC6220435 DOI: 10.2147/ijn.s181440] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
PURPOSE In this study, a double emulsion method for complexing plasmids with stearyl poly-ethylenimine (stPEI) as the core to form human serum albumin (HSA) (plasmid/stPEI/HSA) nanoparticles (NPs) was developed for gene delivery by non-covalently binding onto plasmid/stPEI/HSA nanoparticles with CRISPR/Cas9 or siRNA, which disrupts or silences the expression of programmed cell death ligand-1 (PD-L1) for immunotherapy. MATERIALS AND METHODS Chemically synthesized stearyl-polyethyenimine (stPEI)/plasmids/HSA nanoparticles were maded by double emulsion method. They were characterized by dynamic light scattering (DLS), transmission electron microscope and also evaluated by in vitro study on CT 26 cells. RESULTS stPEI was synthesized by an N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC)-N-hydroxysuccinimide (NHS) reaction, and we found that the degree of substitution was ~1.0 when the ratio of PEI to stearic acid was 1:7 in the reaction. Then, two sgRNA sequences were selected and evaluated for their ability to knock out PD-L1 by decreasing its expression by about 20%. Based on the trend of particle size/zeta potential values as a function of ratio, F25P1 containing 25 μg of plasmid/stPEI/HSA NPs noncovalently bound to 1 μg plasmids via charge-charge interactions was found to be optimal. Its particle size was about 202.7±4.5 nm, and zeta potential was 12.60±0.15 mV. In an in vitro study, these NPs showed little cytotoxicity but high cellular uptake. Moreover, they revealed the potential for transfection and PD-L1 knockout in an in vitro cell model. Furthermore, F25P1S0.5 containing 25 μg of plasmid/stPEI/HSA NPs noncovalently bound to 1 μg of plasmids and 0.5 μg siRNA was prepared to simultaneously deliver plasmids and siRNA. An in vitro study demonstrated that the siRNA did not interfere with the transfection of plasmids and showed a high-transfection efficiency with a synergistic effect on inhibition of PD-L1 expression by 21.95%. CONCLUSION The plasmids/stPEI/HSA NPs could be a promising tool for gene delivery and improved immunotherapy.
Collapse
Affiliation(s)
- Wei-Jie Cheng
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan,
| | - Ling-Chun Chen
- Department of Biotechnology and Pharmaceutical Technology, Yuanpei University of Medical Technology, Hsinchu, Taiwan
| | - Hsiu-O Ho
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan,
| | - Hong-Liang Lin
- School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan,
| | - Ming-Thau Sheu
- School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan,
| |
Collapse
|
161
|
Vio V, Riveros AL, Tapia-Bustos A, Lespay-Rebolledo C, Perez-Lobos R, Muñoz L, Pismante P, Morales P, Araya E, Hassan N, Herrera-Marschitz M, Kogan MJ. Gold nanorods/siRNA complex administration for knockdown of PARP-1: a potential treatment for perinatal asphyxia. Int J Nanomedicine 2018; 13:6839-6854. [PMID: 30498346 PMCID: PMC6207385 DOI: 10.2147/ijn.s175076] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Background Perinatal asphyxia interferes with neonatal development, resulting in long-term deficits associated with systemic and neurological diseases. Despite the important role of poly (ADP-ribose) polymerase 1 (PARP-1) in the regulation of gene expression and DNA repair, overactivation of PARP-1 in asphyxia-exposed animals worsens the ATP-dependent energetic crisis. Inhibition of PARP-1 offers a therapeutic strategy for diminishing the effects of perinatal asphyxia. Methods We designed a nanosystem that incorporates a specific siRNA for PARP-1 knockdown. The siRNA was complexed with gold nanorods (AuNR) conjugated to the peptide CLPFFD for brain targeting. Results The siRNA was efficiently delivered into PC12 cells, resulting in gene silencing. The complex was administered intraperitoneally in vivo to asphyxia-exposed rat pups, and the ability of the AuNR-CLPFFD/siRNA complex to reach the brain was demonstrated. Conclusion The combination of a nanosystem for delivery and a specific siRNA for gene silencing resulted in effective inhibition of PARP-1 in vivo.
Collapse
Affiliation(s)
- Valentina Vio
- Department of Pharmacological and Toxicology Chemistry, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile, .,Program of Molecular and Clinical Pharmacology, Medical Faculty, Universidad de Chile, Santiago, Chile,
| | - Ana L Riveros
- Department of Pharmacological and Toxicology Chemistry, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile,
| | - Andrea Tapia-Bustos
- Program of Molecular and Clinical Pharmacology, Medical Faculty, Universidad de Chile, Santiago, Chile,
| | - Carolyne Lespay-Rebolledo
- Program of Molecular and Clinical Pharmacology, Medical Faculty, Universidad de Chile, Santiago, Chile,
| | - Ronald Perez-Lobos
- Program of Molecular and Clinical Pharmacology, Medical Faculty, Universidad de Chile, Santiago, Chile,
| | - Luis Muñoz
- Chemical Meteorology Section, Comisión Chilena de Energía Nuclear, Santiago, Chile
| | - Paola Pismante
- Chemical Meteorology Section, Comisión Chilena de Energía Nuclear, Santiago, Chile
| | - Paola Morales
- Program of Molecular and Clinical Pharmacology, Medical Faculty, Universidad de Chile, Santiago, Chile, .,Department of Neuroscience, Faculty of Medicine, Universidad de Chile, Santiago, Chile
| | - Eyleen Araya
- Departamento de Ciencias Quimicas, Facultad de Ciencias Exactas, Universidad Andres Bello, Santiago, Chile
| | - Natalia Hassan
- Department of Pharmacological and Toxicology Chemistry, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile, .,Programa Institucional de Fomento a la Investigación, Desarrollo e Innovación, Universidad Tecnológica Metropolitana, Santiago, Chile
| | - Mario Herrera-Marschitz
- Program of Molecular and Clinical Pharmacology, Medical Faculty, Universidad de Chile, Santiago, Chile,
| | - Marcelo J Kogan
- Department of Pharmacological and Toxicology Chemistry, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile, .,Advanced Center for Chronic Diseases (ACCDiS), Santiago, Chile,
| |
Collapse
|
162
|
Melgar-Lesmes P, Luquero A, Parra-Robert M, Mora A, Ribera J, Edelman ER, Jiménez W. Graphene-Dendrimer Nanostars for Targeted Macrophage Overexpression of Metalloproteinase 9 and Hepatic Fibrosis Precision Therapy. NANO LETTERS 2018; 18:5839-5845. [PMID: 30096241 PMCID: PMC6377857 DOI: 10.1021/acs.nanolett.8b02498] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Fibrosis contributes to ∼45% of all deaths in industrialized nations, but no direct antifibrotic therapeutic interventions exist to date. Graphene-based nanomaterials exhibit excellent versatility in electronics, and emerging trends exploit their properties for biomedical applications, especially for drug and gene delivery. We designed constructs of graphene nanostars linked to PAMAM-G5 dendrimer for the selective targeting and delivery of a plasmid expressing the collagenase metalloproteinase 9 under the CD11b promoter into inflammatory macrophages in cirrhotic livers. Graphene nanostars preferentially accumulated in inflammatory macrophages M1 in less than 3 h in a manner unaffected by covalent linkage to dendrimers. Dendrimer-graphene nanostars efficiently delivered the plasmid encoding for metalloproteinase 9 into macrophages, allowing the synthesis and secretion of the metalloproteinase to digest adjacent collagen fibers. In turn, metalloproteinase 9 overexpression promoted the macrophage switch from inflammatory M1 to pro-regenerative M2 in 3 days. This targeted gene therapy reduced selectively and locally the presence of collagen fibers in fibrotic tracts where inflammatory macrophages accumulated in cirrhotic mice without affecting the activation state of hepatic stellate cells. Overall, this treatment significantly reduced hepatic injury and improved liver restoration in mice with liver cirrhosis treated for 10 days. Graphene-dendrimer nanostars targeted the macrophage overexpression of metalloproteinase 9, selectively reducing hepatic fibrosis, and might be a good treatment for diseases associated with fibrosis and inflammatory macrophage accumulation.
Collapse
Affiliation(s)
- Pedro Melgar-Lesmes
- Massachusetts Institute of Technology, Institute for Medical Engineering and Science, 77 Massachusetts Ave, Cambridge, MA 02139, USA
- Department of Biomedicine, School of Medicine, University of Barcelona, 143 Casanova, 08036 Barcelona, Spain
- Fundació Clínic per a la Recerca Biomèdica, Hospital Clínic Universitari, IDIBAPS, 149 Rosselló, 08036 Barcelona, Spain
| | - Aureli Luquero
- Department of Biomedicine, School of Medicine, University of Barcelona, 143 Casanova, 08036 Barcelona, Spain
| | - Marina Parra-Robert
- Biochemistry and Molecular Genetics Service, Hospital Clínic Universitari, IDIBAPS, CIBERehd, 170 Villarroel, 08036 Barcelona, Spain
| | - Adriana Mora
- Department of Biomedicine, School of Medicine, University of Barcelona, 143 Casanova, 08036 Barcelona, Spain
| | - Jordi Ribera
- Biochemistry and Molecular Genetics Service, Hospital Clínic Universitari, IDIBAPS, CIBERehd, 170 Villarroel, 08036 Barcelona, Spain
| | - Elazer R. Edelman
- Massachusetts Institute of Technology, Institute for Medical Engineering and Science, 77 Massachusetts Ave, Cambridge, MA 02139, USA
- Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
| | - Wladimiro Jiménez
- Department of Biomedicine, School of Medicine, University of Barcelona, 143 Casanova, 08036 Barcelona, Spain
- Biochemistry and Molecular Genetics Service, Hospital Clínic Universitari, IDIBAPS, CIBERehd, 170 Villarroel, 08036 Barcelona, Spain
| |
Collapse
|
163
|
Kalaydina RV, Bajwa K, Qorri B, Decarlo A, Szewczuk MR. Recent advances in "smart" delivery systems for extended drug release in cancer therapy. Int J Nanomedicine 2018; 13:4727-4745. [PMID: 30154657 PMCID: PMC6108334 DOI: 10.2147/ijn.s168053] [Citation(s) in RCA: 141] [Impact Index Per Article: 23.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Advances in nanomedicine have become indispensable for targeted drug delivery, early detection, and increasingly personalized approaches to cancer treatment. Nanoparticle-based drug-delivery systems have overcome some of the limitations associated with traditional cancer-therapy administration, such as reduced drug solubility, chemoresistance, systemic toxicity, narrow therapeutic indices, and poor oral bioavailability. Advances in the field of nanomedicine include “smart” drug delivery, or multiple levels of targeting, and extended-release drug-delivery systems that provide additional methods of overcoming these limitations. More recently, the idea of combining smart drug delivery with extended-release has emerged in hopes of developing highly efficient nanoparticles with improved delivery, bioavailability, and safety profiles. Although functionalized and extended-release drug-delivery systems have been studied extensively, there remain gaps in the literature concerning their application in cancer treatment. We aim to provide an overview of smart and extended-release drug-delivery systems for the delivery of cancer therapies, as well as to introduce innovative advancements in nanoparticle design incorporating these principles. With the growing need for increasingly personalized medicine in cancer treatment, smart extended-release nanoparticles have the potential to enhance chemotherapy delivery, patient adherence, and treatment outcomes in cancer patients.
Collapse
Affiliation(s)
| | - Komal Bajwa
- Postgraduate Medical Education, Graduate Diploma and Professional Master in Medical Sciences, School of Medicine, Queen's University
| | - Bessi Qorri
- Department of Biomedical and Molecular Sciences, Queen's University,
| | | | - Myron R Szewczuk
- Department of Biomedical and Molecular Sciences, Queen's University,
| |
Collapse
|
164
|
Zhu D, Shen H, Tan S, Hu Z, Wang L, Yu L, Tian X, Ding W, Ren C, Gao C, Cheng J, Deng M, Liu R, Hu J, Xi L, Wu P, Zhang Z, Ma D, Wang H. Nanoparticles Based on Poly (β-Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy. Mol Ther 2018; 26:2443-2455. [PMID: 30241742 DOI: 10.1016/j.ymthe.2018.07.019] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Revised: 06/24/2018] [Accepted: 07/11/2018] [Indexed: 12/21/2022] Open
Abstract
Persistent high-risk HPV infection is the main cause of cervical cancer. The HPV oncogene E7 plays an important role in HPV carcinogenesis. Currently, HPV vaccines do not offer an effective treatment for women who already present with cervical disease, and recommended periodical cervical screenings are difficult to perform in countries and areas lacking medical resources. Our aim was to develop nanoparticles (NPs) based on poly (β-amino ester) (PBAE) and HPV16 E7-targeting CRISPR/short hairpin RNA (shRNA) to reduce the levels of HPV16 E7 as a preliminary form of a drug to treat HPV infection and its related cervical malignancy. Our NPs showed low toxicity in cells and mouse organs. By reducing the expression of HPV16 E7, our NPs could inhibit the growth of cervical cancer cells and xenograft tumors in nude mice, and they could reverse the malignant cervical epithelium phenotype in HPV16 transgenic mice. The performance of NPs containing shRNA is better than that of NPs containing CRISPR. HPV-targeting NPs consisting of PBAE and CRISPR/shRNA could potentially be developed as drugs to treat HPV infection and HPV-related cervical malignancy.
Collapse
Affiliation(s)
- Da Zhu
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
| | - Hui Shen
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
| | - Songwei Tan
- Tongji School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Zheng Hu
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China; Department of Gynecological Oncology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
| | - Liming Wang
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
| | - Lan Yu
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
| | - Xun Tian
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
| | - Wencheng Ding
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
| | - Ci Ren
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
| | - Chun Gao
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
| | - Jing Cheng
- Department of Obstetrics and Gynecology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China
| | - Ming Deng
- Department of Radiology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China
| | - Rong Liu
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
| | - Junbo Hu
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
| | - Ling Xi
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
| | - Peng Wu
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
| | - Zhiping Zhang
- Tongji School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Ding Ma
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
| | - Hui Wang
- Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
| |
Collapse
|